ATLASATLAS fair value
ATLAS has no fair value for this stock today.
AptaBio Therapeutics (293780.KQ)
AptaBio Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · KOSDAQ · South Korea
₩6,030▲ +4.15%
Prices as of Oct 27, 2026 · KRW
Chance of rising in 1 month
47%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on AptaBio Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On AptaBio Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives AptaBio Therapeutics a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩5,254 and ₩6,713; in 9 out of 10, between ₩4,229 and ₩8,341. Estimated annual volatility is 72%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩185B
- Market cap (USD)
- $139M
- 52-week high
- ₩10,890
- 52-week low
- ₩3,870
- Revenue (12 months)
- ₩4.8B
- Gross margin
- 47.2%
- Operating margin
- -223.0%
- Net margin
- 0.0%
- Beta
- 0.89
What this means
ATLAS does not publish a fair value for 293780.KQ right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks 293780.KQ has traded between ₩3,870 and ₩10,890. Today it is 44.6% below that high and 56% above its low.
Its beta is 0.89: it moves roughly in line with the market.
About the company
AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases.
Want to see everything about AptaBio Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does AptaBio Therapeutics do?
AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases.
What is the chance 293780.KQ goes up next month?
47%: close to a coin flip. In half of the simulated outcomes, 293780.KQ ends the month between ₩5,254 and ₩6,713.
How big is AptaBio Therapeutics and what is its P/E ratio?
AptaBio Therapeutics's market capitalization is ₩185B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is 293780.KQ?
ATLAS estimates annual volatility at 72%. In a typical month, half of the outcomes end between ₩5,254 and ₩6,713.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer